What are the indications, dosing schedule, contraindications, side effects, and monitoring recommendations for bupropion hydrochloride extended‑release?

Bupropion HCl Extended-Release: Comprehensive Clinical Overview

Bupropion HCl ER is FDA-approved for major depressive disorder and seasonal affective disorder, with off-label use for smoking cessation and weight management (in combination with naltrexone). This dopamine-norepinephrine reuptake inhibitor offers unique advantages including minimal sexual dysfunction and weight gain compared to SSRIs 1.

Indications

FDA-Approved Uses

• Major Depressive Disorder (MDD): First-line antidepressant with efficacy comparable to SSRIs and SNRIs 1, 2, 3
• Seasonal Affective Disorder (SAD): Prophylactic treatment initiated in autumn before symptom onset 1

Evidence-Based Off-Label Uses

• Smoking Cessation: Preferred primary therapy option (with or without NRT) for 7-12 weeks 4
• Weight Management: As naltrexone-bupropion ER combination for obesity (BMI ≥30 or ≥27 with comorbidities) 5, 6

Dosing Schedule

Major Depressive Disorder 1

Initial dosing:

• Start 150 mg once daily in the morning
• Increase to target dose of 300 mg once daily as early as day 4 if tolerated
• Maximum dose: 450 mg once daily (only if no response after several weeks at 300 mg)
• Allow ≥24 hours between doses
• Full antidepressant effect may require 4+ weeks

Key administration points:

• Swallow tablets whole—never crush, divide, or chew (increases seizure risk)
• Take in morning to minimize insomnia
• May take without regard to meals

Seasonal Affective Disorder 1

• Initiate in autumn before depressive symptoms begin
• Start 150 mg daily × 1 week, then increase to 300 mg daily
• Continue through winter season
• Taper to 150 mg daily × 2 weeks before spring discontinuation

Smoking Cessation 4

• Days 1-3: 150 mg once daily
• Day 4 through 7-12 weeks: 150 mg twice daily (maximum 300 mg/day)
• Initiate 1-2 weeks prior to quit date
• May extend to 6-12 months for relapse prevention

Contraindications

Absolute Contraindications 1

Bupropion is absolutely contraindicated in:

• Seizure disorder (any history)
• Current or prior bulimia or anorexia nervosa (higher seizure incidence)
• Abrupt discontinuation of alcohol or sedatives (including benzodiazepines)
• Concurrent MAO inhibitor use (allow 14 days washout)
• Known hypersensitivity to bupropion

Critical Clinical Contraindications 4

Avoid in patients with:

• Brain metastases or stroke (seizure risk)
• Closed-angle glaucoma
• Concurrent tamoxifen use (drug interaction)

Side Effects

Common Adverse Effects 4, 1

Most frequent (generally mild and transient):

• Insomnia (minimize by avoiding bedtime doses)
• Dry mouth (20%)
• Headache
• Nausea
• Agitation/motor restlessness (especially first week)
• Constipation
• Dizziness

Management strategy: Temporary dose reduction or short-term sedative-hypnotic (usually not needed beyond first week) 1

Serious Adverse Effects

Seizures 7:

• Risk: approximately 1 in 1,000 (similar to other antidepressants)
• Dose-dependent: Risk increases significantly above 300 mg/day for smoking cessation
• Risk factors: eating disorders, alcohol/sedative withdrawal, brain lesions, concurrent medications lowering seizure threshold

Neuropsychiatric Events 4:

• Black box warning for suicidal thoughts (particularly young adults in first months)
• Monitor for depression, suicidal ideation/behavior, hostility
• Critical finding: EAGLES trial (n=8,144) showed neuropsychiatric adverse events with bupropion were NOT significantly increased vs. nicotine patches or placebo in patients with or without psychiatric disorders 4

Cardiovascular 8:

• No significant increase in major cardiovascular events vs. placebo
• Some studies show modest, transient blood pressure increases (first 8 weeks)

Allergic Reactions 7:

• Risk: 1 in 1,000 to 1 in 10,000
• Includes rash, urticaria, anaphylaxis

Uncommon Side Effects

• Urinary incontinence during sleep (rare with ER formulation) 9

Special Population Dosing

Hepatic Impairment 1

• Severe cirrhosis: Maximum 150 mg every other day (use with extreme caution)
• Mild-moderate cirrhosis: Reduced frequency/dose; use with caution

Renal Impairment 1

• Use with caution; consider reduced frequency/dose
• Close monitoring recommended

Naltrexone-Bupropion ER Combination 5

• Moderate-severe renal impairment: Reduce to 1 tablet twice daily
• End-stage renal disease: Avoid
• Moderate-severe hepatic impairment: Maximum 1 tablet daily

Monitoring Recommendations

Essential Monitoring 4, 10, 6

Baseline and ongoing:

• Neuropsychiatric symptoms: Depression, suicidal ideation, hostility, agitation (especially first weeks)
• Blood pressure: Particularly in first 8 weeks
• Seizure precursors: New-onset headaches, confusion, tremors
• Treatment response: Assess at 4 weeks; if no improvement at 300 mg after several weeks, consider increasing to 450 mg 1

For smoking cessation 4:

• Discontinue if serious neuropsychiatric symptoms develop
• Assess response at 12 weeks on maintenance dose

For weight management (naltrexone-bupropion) 5:

• Discontinue after 12 weeks if <5% total body weight loss (poor responder)
• Monitor mood changes closely

Drug Interactions

Critical Interactions 4, 1

• MAO inhibitors: Contraindicated; 14-day washout required
• Tamoxifen: Contraindicated (bupropion may reduce tamoxifen efficacy)
• Opioids (with naltrexone-bupropion): May precipitate withdrawal or reduce analgesic efficacy; discontinue before procedures requiring opioids 5
• Medications lowering seizure threshold: Use extreme caution

Switching Between Antidepressants 1

When switching from other bupropion formulations:

• Maintain same total daily dose when possible
• Example: 300 mg/day immediate-release (100 mg TID) → 300 mg once daily ER

Clinical Pearls

Advantages Over Other Antidepressants 2, 3, 11

• Minimal sexual dysfunction (lowest among newer antidepressants)
• No weight gain (may cause weight loss)
• Less somnolence than SSRIs and TCAs
• Useful in comorbid depression and smoking
• May benefit patients with depression and ADHD symptoms 12

Common Pitfalls to Avoid

1. Never crush or chew tablets: Dramatically increases seizure risk 1
2. Don't exceed 300 mg/day for smoking cessation: Higher doses increase seizure risk without added benefit 4
3. Avoid bedtime dosing: Causes insomnia 1
4. Don't use in active eating disorders: Significantly elevated seizure risk 1
5. Screen for alcohol/sedative withdrawal: Contraindicated during acute withdrawal 1

When to Choose Bupropion

Ideal candidates:

• Patients concerned about sexual dysfunction or weight gain
• Comorbid depression and smoking
• Comorbid depression and ADHD symptoms
• Seasonal affective disorder
• Patients who failed SSRIs due to side effects 6, 11

Avoid in:

• Any seizure history or risk factors
• Eating disorders (current or past)
• Brain lesions or metastases
• Active alcohol/substance withdrawal
• Patients requiring opioid therapy (if considering naltrexone-bupropion)

Efficacy Expectations

• Depression: Comparable to SSRIs and SNRIs; full effect in 4+ weeks 2, 3
• Smoking cessation: OR 2.07 vs. placebo; less effective than varenicline but more effective than nicotine patch alone 4
• Weight loss (naltrexone-bupropion): 4.9-6.1% at 56 weeks vs. 1.3-2.4% placebo 5, 6